| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Maria Nadinskaia, Marina Maevskaya, Vladimir Ivashkin, Khava Kodzoeva, Irina Pirogova, Evgeny Chesnokov, Alexander Nersesov, Jamilya Kaibullayeva, Akzhan Konysbekova, Aigul Raissova, Feruza Khamrabaeva and Elena Zueva |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Marina Maevskaya, MD, Professor, Vasilenko Clinic of internal diseases propedeutics, gastroenterology and hepatology, University Clinical Hospital №2,, First Moscow State Medical University, Bolshaya Pirogovskaya ul., 19s1, Москва 119991, Russia. liver.orc@mail.ru |
| Key Words |
Ursodeoxycholic acid; Nonalcoholic fatty liver disease; Liver function tests; Fatty liver index; Carotid intima-media thickness; Atherosclerotic cardiovascular disease |
| Core Tip |
An open-label, multicenter, international noncomparative trial demonstrated the effect of ursodeoxycholic acid (UDCA) on hepatic steatosis and fibrosis, atherogenesis, and atherosclerotic cardiovascular disease risk in 174 ultrasound-diagnosed nonalcoholic fatty liver disease patients who received 15 mg/kg/d UDCA for 6 mo and were prescribed lifestyle modifications with diet and exercise. UDCA had a bidirectional positive effect on the liver and cardiovascular system in patients with and without > 5% weight loss: It improved liver enzymes, lipid profiles, and hepatic steatosis in addition to improving carotid intima-media thickness and atherosclerotic cardiovascular disease risk. |
| Publish Date |
2021-03-11 08:31 |
| Citation |
Nadinskaia M, Maevskaya M, Ivashkin V, Kodzoeva K, Pirogova I, Chesnokov E, Nersesov A, Kaibullayeva J, Konysbekova A, Raissova A, Khamrabaeva F, Zueva E. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2021; 27(10): 959-975 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i10/959.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i10.959 |
